DISCOVERY




Drug discovery

With more than 30 years of experience, our subject matter experts partner with you to help accelerate your discovery program towards the clinic and commercialization with our best-in-class expertise and capabilities in medicinal chemistry, cell biology, CADD, structural biology and DMPK. Whether you require a particular expertise or a complete, experienced <u>integrated small molecule discovery</u> team, Curia can provide a high-performance solution to help turn your vision into reality.



Discovery and Development Capabilities



Discovery platform

Leverage Curia's small molecule discovery platform at our U.S., India and Spain-based facilities for worldwide access to premium CRO/CDMO services

| | Target ID | Hit ID | H2L | Lead Op | Candidate Selection |
|---|---|---|---|---|---|
| | Cell Line Enginee Validation & Mini | | elopment, | | |
| Cell Biology | Cellular High-Throughput Screening Hit Finding by High-Content Imaging, SPE-MS/MS, AlphaScreen, HTRF or FLIPR | | | | |
| | | | Routine SAR Testing Apoptosis & Cell Via | Phenotypic Profiling b bility Assays 3D Cell M | by High-Content Imaging odels |
| | Biomarker Assay Development & Validation | | | | |
| Assay Development & Screening | Biochemical/Biop and Substrate De | | High Through 120k Proprieta Small Molecul | out Screening (HTS) iry & 500k Commercial e Library | Selectivity Testing and Mechanism Of Action Studies |
| | Enzymes, Receptor Transporters, Sig and ProteinProte | ors, nal Transduction in Interactions | (FI,HTRF,Alpha | abel Dependent Screen, Lumi. etc.) pidFire SPE-MS/MS) | Proteomics and High-Resolution LC/MS Biophysical characterization Protein Therapeutic Bioanalytical PK Study |
| Synthetic and medicinal chemistry | Medicinal Chemistry/Peptide Synthesis/ADC Chemistry/Library Generation/Protein Degraders | | | | |
| | | | Target Design | | |
| | Chemical Biolog | Sy | Hit Expansion | | |
| | | eference compou Labeled compou | | Route Scouting/Route O | Optimization/Process Development |
| | | | | stry/Chiral Seprations/Sta tellectual Property Gener | |
| CADD | Computational Chemistry/Computer-Aided Drug Discovery/Structure Based Drug Discovery | | | | |
| | Library Designs/ Screening | Virtual | Physicochemica | al Properties/MPO Calcu | lations/ ADMET Liabilities |
| | Binding site models based on homology or crystal/CryoEM | | | | |
| Protein Sciences | Prospective Expression Hot Screening Protein Expression and Purification Methods Development Reagent, BioProcess or Crystallography Grade Product | | | | |
| | Bioconjugation and Analysis ADCs and AOCs non-GMP | | | | |
| | Protein Analysis: Native & SDA-PAGE Intact & bottom-up MS SPR DSF UPLC HPLC SEC/MALS/RI DLS LAL Standarad and Digital Western blotting | | | | |
| | Structural Biology Protein Crystallography Cryo-EM Modeling Structure-Based Drug Discovery SBDD | | | | |
| DMPK | | | Solubility Pe | rmeability Stability D | rug -Drug Interaction |
| | Protein binding CYP inhibition Hepatocyte clearance Blood-plasma partitioning | | | | |
| | | | | | Cytotoxicity Metabollic profilling Ames screening hERG inhibition |
| Fermentation | | | | 9 | Strain selection and improvement |